About
James Li joined Frazier Life Sciences as a Venture Partner in 2024, with more than 30 years in biotech investing, company building, and management, and a focus on cross-border opportunities. He co-founded and served as CEO of JW Therapeutics (2016–2024), a cell therapy company behind China's first domestically developed CAR-T therapy, and previously held the founding General Manager role for Greater China at Amgen. Earlier, he was a Partner in the life sciences practice at Kleiner Perkins Caufield & Byers and spent over 15 years at Merck & Co. in clinical research, regulatory affairs, and product development roles. He holds an M.D. from Shanghai Medical University and an M.S. in Microbiology from the University of Montana.
Invests in
Biotech
Experience
- Frazier Life SciencesVenture Partnercurrent2024 — presentUnited States
- JW Therapeutics 药明巨诺Co-Founder and Non-Executive Board Membercurrent2024 — present
- JW Therapeutics 药明巨诺Interim Board Chairman2024
- JW Therapeutics 药明巨诺Co-Founder and CEO2016 — 2024Shanghai, China
- AmgenVice President and General Manager, Greater China2012 — 2015Shanghai, China
- Kleiner Perkins Caufield & ByersPartner2006 — 2011
- MerckFranchise Head, Hypertension, AP1991 — 2006
Education
- Shanghai Medical University, ChinaMedical Degree, Medicine
- University of MontanaMaster of Science (M.S.), Microbiology
Skills & more
+1 more
Business StrategyFrom James's professional profile.
Same school
Shared employers
Also worked at Frazier Life Sciences46
+ 40 more
Also worked at Amgen53
+ 47 more
Also worked at Kleiner Perkins Caufield & Byers99
+ 93 more
Also worked at Merck90
+ 84 more
